Clicky

Valneva(VLA) News

Date Title
Oct 11 High Growth Tech Stocks In France October 2024
Oct 10 Valneva Hosts Investor Day in New York City
Oct 9 Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges
Oct 9 Exclusive Networks And 2 High Growth Tech Stocks In France
Oct 8 Exploring Three High Growth Tech Stocks in France
Jul 26 Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
Jul 4 Declaration of shares and voting rights - Valneva SE - June 30, 2024
Jul 1 Valneva’s chikungunya vaccine gains EC’s market authorisation
Jul 1 Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®
Jun 26 Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
Jun 24 Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
Jun 24 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
May 21 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
Jan 10 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
Dec 20 Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
Dec 6 VALNEVA Declaration of shares and voting rights - November 30, 2023
Dec 5 Pfizer, after delay, completes enrollment in Lyme vaccine trial
Dec 4 Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
Dec 4 Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
Nov 27 EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment